Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis

被引:79
|
作者
Balestro, Elisabetta [1 ]
Calabrese, Fiorella [1 ]
Turato, Graziella [1 ]
Lunardi, Francesca [1 ]
Bazzan, Erica [1 ]
Marulli, Giuseppe [1 ]
Biondini, Davide [1 ]
Rossi, Emanuela [1 ]
Sanduzzi, Alessandro [2 ]
Rea, Federico [1 ]
Rigobello, Chiara [1 ]
Gregori, Dario [1 ]
Baraldo, Simonetta [1 ]
Spagnolo, Paolo [1 ]
Cosio, Manuel G. [1 ,3 ]
Saetta, Marina [1 ]
机构
[1] Univ Padua, Dept Cardiac Thorac & Vasc Sci, Padua, Italy
[2] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy
[3] McGill Univ, Meakins Christie Labs, Div Resp, Montreal, PQ, Canada
来源
PLOS ONE | 2016年 / 11卷 / 05期
关键词
PATHOGENESIS; CLASSIFICATION; MANAGEMENT; PHENOTYPES; PNEUMONIA; TARGET;
D O I
10.1371/journal.pone.0154516
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The clinical course in idiopathic pulmonary fibrosis (IPF) is highly heterogeneous, with some patients having a slow progression and others an accelerated clinical and functional decline. This study aims to clinically characterize the type of progression in IPF and to investigate the pathological basis that might account for the observed differences in disease behavior. Clinical and functional data were analyzed in 73 IPF patients, followed long-time as candidates for lung transplantation. The forced vital capacity (FVC) change/year (< or >= 10% predicted) was used to define "slow" or "rapid" disease progression. Pathological abnormalities were quantified in the explanted lung of 41 out of 73 patients undergoing lung transplantation. At diagnosis, slow progressors (n = 48) showed longer duration of symptoms and lower FVC than rapid progressors (n = 25). Eleven slow and 3 rapid progressors developed an acute exacerbation (AE) during follow-up. Quantitative lung pathology showed a severe innate and adaptive inflammatory infiltrate in rapid progressors, markedly increased compared to slow progressors and similar to that observed in patients experiencing AE. The extent of inflammation was correlated with the yearly FVC decline (r = 0.52, p = 0.005). In conclusion an innate and adaptive inflammation appears to be a prominent feature in the lung of patients with IPF and could contribute to determining of the rate of disease progression.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] PREDICTION OF DISEASE PROGRESSION IN IDIOPATHIC PULMONARY FIBROSIS
    WELLS, AU
    DUBOIS, RM
    [J]. EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (04) : 637 - 639
  • [2] The Proteome Signature Of Disease Progression In Idiopathic Pulmonary Fibrosis
    O'Dwyer, D. N.
    Ashley, S.
    Xia, M.
    Murray, S.
    Grant, E.
    White, E. S.
    Flaherty, K. R.
    Martinez, F. J.
    Moore, B. B.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [3] Comparison of disease progression subgroups in idiopathic pulmonary fibrosis
    Karkkainen, Miia
    Kettunen, Hannu-Pekka
    Nurmi, Hanna
    Selander, Tuomas
    Purokivi, Minna
    Kaarteenaho, Riitta
    [J]. BMC PULMONARY MEDICINE, 2019, 19 (01)
  • [4] Risk factors for disease progression in idiopathic pulmonary fibrosis
    Raghu, Ganesh
    Ley, Brett
    Brown, Kevin K.
    Cottin, Vincent
    Gibson, Kevin F.
    Kaner, Robert J.
    Lederer, David J.
    Noble, Paul W.
    Song, Jin Woo
    Wells, Athol U.
    Whelan, Timothy P.
    Lynch, David A.
    Humphries, Stephen M.
    Moreau, Emmanuel
    Goodman, Krista
    Patterson, Scott D.
    Smith, Victoria
    Gong, Qi
    Sundy, John S.
    O'Riordan, Thomas G.
    Martinez, Fernando J.
    [J]. THORAX, 2020, 75 (01) : 78 - 80
  • [5] Pirfenidone reduced disease progression in idiopathic pulmonary fibrosis
    Lake, Fiona
    [J]. ANNALS OF INTERNAL MEDICINE, 2014, 161 (08)
  • [6] Comparison of disease progression subgroups in idiopathic pulmonary fibrosis
    Miia Kärkkäinen
    Hannu-Pekka Kettunen
    Hanna Nurmi
    Tuomas Selander
    Minna Purokivi
    Riitta Kaarteenaho
    [J]. BMC Pulmonary Medicine, 19
  • [7] Autoantibodies are associated with disease progression in idiopathic pulmonary fibrosis
    Koether, Katerina
    Besnard, Valerie
    Sandig, Hilary
    Carruthers, Alan
    Miranda, Elena
    Grootenboer-Mignot, Sabine
    Taille, Camille
    Chevret, Sylvie
    Valeyre, Dominique
    Nunes, Hilario
    Israel-Biet, Dominique
    Lim, Wei Keat
    Cottin, Vincent
    Corkill, Dominic
    Dobson, Claire
    Groves, Maria
    Ferraro, Franco
    Guenzi, Edouard
    Huang, Ling
    Sulikowski, Michal
    Mailleux, Arnaud
    Murray, Lynne Anne
    Mustelin, Thomas
    Strickland, Ian
    Sleeman, Matthew A.
    Crestani, Bruno
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2023, 61 (05)
  • [8] Disease Progression in Idiopathic Pulmonary Fibrosis FVC Is Not Enough
    Behr, Juergen
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 196 (09) : 1094 - 1095
  • [9] Idiopathic Pulmonary Fibrosis Nintedanib slows the Progression of the Disease
    Weiss, Johannes
    [J]. PNEUMOLOGIE, 2016, 70 (07): : 434 - 434
  • [10] Predictive biomarkers of disease progression in idiopathic pulmonary fibrosis
    Zhu, Weiwei
    Liu, Chunquan
    Tan, Chunting
    Zhang, Jie
    [J]. HELIYON, 2024, 10 (01)